Cambrex (CBM) and Pacira Pharmaceuticals (PCRX) Head-To-Head Survey

Cambrex (NYSE: CBM) and Pacira Pharmaceuticals (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cambrex and Pacira Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambrex 0 0 3 0 3.00
Pacira Pharmaceuticals 1 8 8 0 2.41

Cambrex currently has a consensus price target of $62.33, indicating a potential upside of 29.32%. Pacira Pharmaceuticals has a consensus price target of $49.38, indicating a potential upside of 9.14%. Given Cambrex’s stronger consensus rating and higher probable upside, analysts clearly believe Cambrex is more favorable than Pacira Pharmaceuticals.

Volatility and Risk

Cambrex has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Pacira Pharmaceuticals has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500.

Profitability

This table compares Cambrex and Pacira Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cambrex 18.79% 23.42% 16.19%
Pacira Pharmaceuticals -18.25% -13.77% -6.34%

Earnings & Valuation

This table compares Cambrex and Pacira Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cambrex $490.64 million 3.22 $81.67 million $3.00 16.07
Pacira Pharmaceuticals $276.37 million 6.64 -$37.94 million ($1.31) -34.54

Cambrex has higher revenue and earnings than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than Cambrex, indicating that it is currently the more affordable of the two stocks.

Summary

Cambrex beats Pacira Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

What are top analysts saying about Cambrex Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cambrex Co. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit